5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phas... by J. Gligorov, X. Pivot, B. Ataseven, M. De Laurentiis, A. Llombart, K.H. Jung, A. Manikhas, H.A. Azim, A. Alexandrou, K. Gupta, L. Herraez-Baranda, N. Tosti, E. Restuccia

Get full text